Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Luciano José Megale CostaSaurabh ChhabraEva MedvedovaBhagirathbhai R DholariaTimothy Martin SchmidtKelly N GodbyRebecca W SilbermannBinod DhakalSusan BalSmith GiriAnita D SouzaAric C HallPamela HardwickJames OmelRobert Frank CornellParameswaran N HariNatalie S CallanderPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Dara-KRd, AHCT, and MRD response-adapted consolidation leads to high rate of MRD negativity in NDMM. For patients with 0 or 1 HRCA, this strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance.